Form 4: Terns Pharmaceuticals Director Hongbo Lu Acquires Stock Options in Lieu of Cash Retainer
SEC Form 4
Director Hongbo Lu of Terns Pharmaceuticals acquired 10,657 stock options in lieu of a $40,000 cash retainer for 2025.
Summary
- Hongbo Lu, a director at Terns Pharmaceuticals, received 10,657 stock options on February 1, 2025.
- These options were granted in place of a $40,000 cash retainer fee for the year 2025.
- The options have an exercise price of $4.46 per share.
- The options vest monthly starting January 1, 2025, with full vesting by January 1, 2026.
- The options expire on January 31, 2035.
Sentiment
Score: 7
Explanation: The document reflects a standard compensation practice, indicating a positive alignment of interests between the director and the company. There is no indication of any negative issues.
Positives
- The director's decision to take stock options instead of cash aligns his interests with the company's long-term performance.
- The vesting schedule encourages the director's continued engagement with the company.
Industry Context
It is common practice for companies to offer stock options to directors as part of their compensation packages, aligning their interests with shareholders.
Comparison to Industry Standards
- Granting stock options to directors is a standard practice in the pharmaceutical industry, often used to incentivize long-term value creation.
- The vesting schedule of 12 months is typical for director stock options, ensuring continued engagement.
- The exercise price of $4.46 is a key factor in determining the value of the options, and is likely based on the current market price of the stock at the time of grant.
- Companies like Amgen, Gilead, and Regeneron also use stock options as part of their director compensation packages, with similar vesting schedules and exercise prices based on market conditions.
Stakeholder Impact
- Shareholders may view this as a positive sign of director commitment to the company's long-term success.
- The director's decision to take stock options instead of cash reduces the company's immediate cash outflow.
Key Dates
| Date | Description |
|---|---|
| 02/01/2025 | Date of the stock option grant. |
| 01/01/2025 | Start date for monthly vesting of the options. |
| 01/01/2026 | Date of full vesting of the options. |
| 01/31/2035 | Expiration date of the stock options. |
| 02/03/2025 | Date the form was signed. |
Keywords
stock options, director compensation, insider trading, Terns Pharmaceuticals, Hongbo Lu, equity, vesting
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.